Daniel K. Spiegelman
Known title: DirectorCIK: 0001238403
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Transaction History
| KYTX | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 | View on chart |
| MYGN | ▼ Sell | Open Market | 3,788 | $84K | 6/4/2024 | View on chart |
| MYGN | ▼ Sell | Open Market | 3,788 | $83K | 6/3/2024 | View on chart |
| MYGN | ▼ Sell | Open Market | 8,638 | $199K | 6/2/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 15,151 | $0 | 6/1/2023 | View on chart |
| MYGN | ▼ Sell | Open Market | 6,424 | $124K | 6/6/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 17,275 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.